Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
10
×
life sciences
national blog main
boston top stories
san francisco blog main
biotech
national top stories
san francisco top stories
cancer
clinical trials
blueprint medicines
fda
indiana blog main
indiana top stories
roche
seattle blog main
seattle top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
national
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
avapritinib
boston
cancer drugs
deals
eli lilly
europe blog main
investing
loxo oncology
What
cancer
10
×
drug
10
×
fda
medicine
medicines
approval
blueprint
targets
biotech
genetic
ipo
marketing
new
research
ret
therapeutics
tiny
adding
address
ahead
alzheimer's
ambien
american
announced
annual
approved
approves
asco
attendees
attention
bad
bets
black
boost
brain
camp’s
candidate
carries
case
cash
Language
unset
Current search:
drug
×
cancer
×
" boston blog main "
×
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
@xconomy.com
4 years ago
Chasing Blueprint, Deciphera Plans FDA Filing for GI Cancer Drug
@xconomy.com
5 years ago
Can Tiny Drug Doses (and One Woman’s Fortune) Fight the Most Vicious Cancer?
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
To Boost Cancer Pipeline, Gilead Bets at Least $50M on Startup Tango
@xconomy.com
6 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More